Ann: Positive FDA Pre-IND meeting guides IHL-42X development, page-23

Even if the modest assessment of revenue for IHL or acquirer annually from this drug is US $1Bn globally, that values this part of the business alone 4-5X which is about $4Bn based of the OSA vertical. As long as we can realise that potential either MC or sale of OSA drug I am a happy camper!

Alternatively we can license this to a big pharma (BP) and let them take care of marketing and distribution but we get at least 10% licensing fees on $1Bn annual sales that equates to US $100Mn annual revenues to IHL- still not a bad outcome IMO.